These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31850350)

  • 1. A Liver Model of Infantile-Onset Pompe Disease Using Patient-Specific Induced Pluripotent Stem Cells.
    Yoshida T; Jonouchi T; Osafune K; Takita J; Sakurai H
    Front Cell Dev Biol; 2019; 7():316. PubMed ID: 31850350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells.
    Yoshida T; Awaya T; Jonouchi T; Kimura R; Kimura S; Era T; Heike T; Sakurai H
    Sci Rep; 2017 Oct; 7(1):13473. PubMed ID: 29044175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient.
    Sato Y; Kobayashi H; Higuchi T; Shimada Y; Era T; Kimura S; Eto Y; Ida H; Ohashi T
    Mol Ther Methods Clin Dev; 2015; 2():15023. PubMed ID: 26199952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.
    Higuchi T; Kawagoe S; Otsu M; Shimada Y; Kobayashi H; Hirayama R; Eto K; Ida H; Ohashi T; Nakauchi H; Eto Y
    Mol Genet Metab; 2014 May; 112(1):44-8. PubMed ID: 24642446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
    Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
    Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
    Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
    Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
    Fukuhara Y; Fuji N; Yamazaki N; Hirakiyama A; Kamioka T; Seo JH; Mashima R; Kosuga M; Okuyama T
    Mol Genet Metab Rep; 2018 Mar; 14():3-9. PubMed ID: 29124014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DeepNEU: Artificially Induced Stem Cell (aiPSC) and Differentiated Skeletal Muscle Cell (aiSkMC) Simulations of Infantile Onset POMPE Disease (IOPD) for Potential Biomarker Identification and Drug Discovery.
    Esmail S; Danter WR
    Front Cell Dev Biol; 2019; 7():325. PubMed ID: 31867331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review.
    Schoser B; Raben N; Varfaj F; Walzer M; Toscano A
    Mol Genet Metab Rep; 2024 Jun; 39():101085. PubMed ID: 38698877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
    Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS;
    Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.
    Raval KK; Tao R; White BE; De Lange WJ; Koonce CH; Yu J; Kishnani PS; Thomson JA; Mosher DF; Ralphe JC; Kamp TJ
    J Biol Chem; 2015 Jan; 290(5):3121-36. PubMed ID: 25488666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy.
    Muñoz S; Bertolin J; Jimenez V; Jaén ML; Garcia M; Pujol A; Vilà L; Sacristan V; Barbon E; Ronzitti G; El Andari J; Tulalamba W; Pham QH; Ruberte J; VandenDriessche T; Chuah MK; Grimm D; Mingozzi F; Bosch F
    Mol Metab; 2024 Mar; 81():101899. PubMed ID: 38346589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
    Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
    Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy.
    Moravej H; Amirhakimi A; Showraki A; Amoozgar H; Hadipour Z; Nikfar G
    Iran J Med Sci; 2018 Mar; 43(2):218-222. PubMed ID: 29749992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical infantile-onset Pompe disease with good prognosis from mainland China: A case report.
    Zhang Y; Zhang C; Shu JB; Zhang F
    World J Clin Cases; 2022 Apr; 10(10):3278-3283. PubMed ID: 35603335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
    Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
    Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.